Takeda (TSE:4502/NYSE:TAK) today announced that the recently FDA-approved HyHub and HyHub Duo devices are now available in the U.S. for patients 17 years of age and older, as prescribed, who are ...

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Takeda (TSE:4502/NYSE:TAK) today announced that the Japanese Ministry of Health, Labour and Welfare has approved the use of CUVITRU™ [Immune Globulin ...

HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] is the First and Only Facilitated Subcutaneous Immunoglobulin (fSCIG) Approved in Japan for Agammaglobulinemia and ...

Key companies in the global subcutaneous immunoglobulin market include Grifols S.A., CSL Behring LLC, Shire Plc., Biotest AG, Kedrion S.p.A., Octapharma AG, Baxalta ...

SAN ANTONIO — Cutaquig provided safe and effective dosing flexibility for patients with primary immunodeficiency disease, according to data presented at the American Academy of Allergy, Asthma & ...

- Hizentra ® is the #1 immune globulin prescribed for Primary Immunodeficiency (PI) in the U.S. - Hizentra is the first and only subcutaneous immune globulin (SCIg) treatment approved for Chronic ...

KING OF PRUSSIA, Pa., Aug. 9, 2021 /PRNewswire/ — Global biotherapeutics leader CSL Behring today announced that the European Academy of Neurology (EAN) and Peripheral Nerve Society (PNS) Task Force ...

MAHWAH, N.J.--(BUSINESS WIRE)-- KORU Medical Systems, Inc. (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and ...

Dublin, Sept. 05, 2025 (GLOBE NEWSWIRE) -- The "Immunoglobulin Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2025 ...